The University of Maryland has quietly started its next capital fundraising campaign with an eye on raising more than $1 billion.
In a wide-ranging conversation with the Washington Business Journal, President Wallace Loh said he hopes to build on his recent success, raising more than the record-setting multiyear “Great Expectations” campaign in the next three years. The campaign is in a quiet phase and won’t be officially launched until at least half of the goal is raised.
A new report shows that participation of corporate venture capitalists in life sciences investing has been increasing.
The MoneyTree report from the National Venture Capital Association and PricewaterhouseCoopers with data from Thomson Reuters show that in the nine months of the year, corporate VCs pumped a total of $1.18 billion into life sciences startups. Whereas in all of 2014, corporate VCs have shelled out $1.2 billion. Back in 1995, as far back as the MoneyTree report goes back, corporate VCs invested only $70.7 million dollars.
The U.S. Food and Drug Administration on Tuesday approved Swiss drugmaker Roche’s Cotellic to be used in combination with the company’s Zelboraf drug to treat BRAF V600 mutation-positive advanced melanoma.
Roche is counting on the addition of Cotellic to help it revive flagging sales of five-year-old Zelboraf, which dropped 25 percent during the first nine months of 2015 and has been under intense pressure from rivals’ drugs as the standard of care moves to combination therapy.
The Princeton Review and Entrepreneur magazine today announced the results of The Princeton Review’s 10th annual survey that names the 25 undergraduate and 25 graduate schools best for entrepreneurship studies.
Babson College captured the #1 spot on the undergraduate entrepreneurship programs ranking list for the 4th consecutive year. Harvard University finished #1 on the graduate entrepreneurship programs list for the 2nd consecutive year.
The I-Corps™ at NIH program, supported by President Obama’s Strategy for American Innovation, aims to support biomedical innovation and translation, with the goal of expediting the development and commercialization of a range of technologies to address the leading causes of death and disability in the United States. I-Corps™ participants will receive lessons on how to build a scalable business model as well as entrepreneurial trainings, and mentorship opportunities. In addition, modest funding will be provided to teams to assist them in translating their ideas from the lab into a viable product on the market and to help them avoid common failure points.
NHLBI Small Business programs support the development of new technologies from lab to market.
The NIH will host a webinar on the I-Corps™ at NIH program to provide information about the program, eligibility, benefits, and how to apply. Participants will also be offered an opportunity to engage with program leaders. Registration for the webinar is free, but required.
Three years into President Wallace Loh’s campus-wide initiative to engage students of all majors in innovation and entrepreneurship (I&E), the University of Maryland has been named a Top 25 School for Entrepreneurship Studies by The Princeton Review.
In the 2016 rankings released today and featured in the December issue of Entrepreneur Magazine, UMD climbed 11 spots from last year to No. 10 for undergraduate entrepreneurship education. This marks the fifth consecutive year that UMD has been named a top 25 program, and the first time the university has ranked in the top 10. UMD also ranked No. 6 among public universities and No. 18 for its graduate program.
Lupus is a poorly-understood autoimmune disorder that is characterised by joint pain and swelling, rashes on the skin and extreme fatigue, with some patients experiencing intermittent flare-ups which can lead to severe and even life-threatening symptoms.
GSK reported new phase III data on a new subcutaneous formulation of its market-leading Benlysta (belimumab) product – which was approved as in one-hour infusion formulation for SLE in 2011, the first new therapy for the disease in five decades.
The Chesapeake Regional Tech Council (CRTC) named a permanent leader to succeed former executive director Kris Shock.
Tami Howie assumed the helm of the Maryland organization, which looks to organize and connect the state’s tech sector, on Nov. 2.
British biopharma startup NightstaRx, which develops gene therapy for inherited retinal dystrophies, just closed out a $35 million Series B led by New Enterprise Associates. The funding will help NightstaRx advance several gene therapies into human trials, as well as expand its existing clinical program for the treatment of choroideremia.
The company’s approach to gene therapy involves harnessing an adeno-associated viral vector to deliver a corrective gene into patients with inherited progressive blindness. Specifically, to treat choroideremia, NightstaRx delivers a wild-type copy of the Rab-escort protein 1 (REP-1) gene (AAV2-REP1) straight into the retinal cells.
The University of Maryland BioPark is looking to add another building that would feature a biotech incubator as its anchor.
Real estate firm Wexford Science + Technology is seeking public financing for a future building at 873 W. Baltimore St., which would be key in attracting a new branch of the Massachusetts-based Cambridge Innovation Center to Baltimore, officials say.
